Videos

Richard Kim, MD, discussed key findings of the phase 1b KEYNOTE-651 trial, examining pembrolizumab plus standard chemotherapy in patients with microsatellite-stable or mismatch repair–proficient colorectal cancer.

Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal and other solid tumor malignancies.

During the 2022 American Society of Clinical Oncology Annual Meeting, Richard Kim, MD, discusses the rationale for the phase 1b KEYNOTE-651 trial examining pembrolizumab plus chemotherapy in metastatic colorectal cancer.

Hope S. Rugo, MD, spoke about results of the phase 3 TROPiCS-02 trial examining sacituzumab govitecan vs physicians’ choice chemotherapy for patients with hormone receptor–positive, HER2-negative advanced breast cancer presented at ASCO 2022.

Depth of response and treatment duration in patients with newly diagnosed MM are discussed by Dr Fonseca.

Biagio Ricciuti, MD, spoke about combination immunotherapy regimens for patients with non–small cell lung cancer who did not respond well to prior treatment.

Broad discussion on novel therapies, including bispecifics and CAR-T therapies, that are evolving the treatment landscape of multiple myeloma.

Panelists take a broad look at treatment selection and sequencing through multiple lines of therapy in patients with multiple myeloma.

Biagio Ricciuti, MD, spoke about patients with non–small cell lung cancer with a very high PD-L1 tumor proportion score of 90% or more who were treated with first-line pembrolizumab monotherapy.

Amrita Y. Krishnan, MD, spoke about the use of teclistamab vs real-world data in patients with relapsed/refractory multiple myeloma.

Thierry Facon, MD, spoke about treatment combinations that have seen success in patients with multiple myeloma, as well as where future research should be focused.

Experts muse on the unmet needs of multiple myeloma, and exciting investigational therapies on the horizon.

A look at the role of bispecifics and CAR T-cell therapies in the multiple myeloma treatment landscape.

Drs Tom Powles and Brian Shimkus muse on the unmet needs of kidney cancers and treatments on the horizon to look forward to.

A discussion on how patient risk groups play into deciding on the appropriate treatment for renal cell carcinoma.

Drs Bishop and Bank close by outlining remaining unmet needs in CLL, emerging regimens, and hopes for the future of care.

Mehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.

Michael R. Bishop, MD, and Bruce B. Bank, MD, summarize key takeaways from the ELEVATE-RR study and discuss the clinical implications of using BTK inhibitors in patients with CLL.

Arnab Basu, MD, MPH, FACP, weighs in on novel therapeutic targets and emerging regimens that may further improve kidney cancer outcomes.

Drs Bishop and Bank discuss ELEVATE-RR safety data.

Drs. Cohen and Lewis close by outlining ongoing clinical trials in CRC and hopes for the future of care.

Dr Rafael Fonseca, MD, provides insight on the evidence around quadruplet versus triplet therapies in patients with newly diagnosed, transplant-eligible multiple myeloma, and how to select the appropriate treatment regimen for this patient population.

Sara Hurvitz, MD, spoke about ongoing clinical trials in which trastuzumab deruxtecan is being investigated with the use of brain metastases.

Jaffer A. Ajani, MD, spoke about the recent approvals of nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with esophageal squamous cell carcinoma.

Moving to the last patient case of newly diagnosed multiple myeloma, expert panelists work together to define patient frailty in this setting and discuss how frail patients are treated in practice.

Shared insight on optimizing selection and use of daratumumab-containing regimens in NDMM, with regard for clinical trial readouts in this setting.

Sara Hurvitz, MD, spoke which patients would benefit most from fam-trastuzumab deruxtecan and what the next research steps will be.

Sara Hurvitz, MD, spoke to the difficulty of treating HER2-positive and advanced HER2-positive breast cancer and how the efficacy of novel agents such as fam-trastuzumab deruxtecan-nxki could make a difference in treating the disease.

The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.

Xiaoli Mi, MD, presents data from a paper in Blood on the determination of outcomes for adolescents and young adults with ALL.